Promedior Orphan Status 2014

September 2, 2014

Promedior, Inc. has been granted orphan drug designation for PRM-151 for the treatment of myelofibrosis by the U.S. Food and Drug Administration (FDA). Click here to read more.

Receive updates on the latest MPN news & events.

Find out ways you can help support MPN patients and researchers.

x

NEVER MISS AN UPDATE

Get free, timely information on living with an MPN.

Subscribe